Abstract
We have not added the abstract for this paper yet. The publisher's page has the full record.
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial
The Lancet Neurology · Vol. 7, pp. 483-493 Published January 1, 2008
More on these topics
Browse all publications →-
2026 · Nat Med
Target product profiles for treatments to delay or prevent symptomatic Alzheimer's disease
-
2025 · Neurotherapeutics
Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer's disease
-
2025 · J Prev Alzheimers Dis
Donanemab: Appropriate use recommendations
-
2024 · Alzheimer's Association International Conference (AAIC)
Navigating the Complexities of Alzheimer's Clinical Trials: The Perils of Small Molecule Studies and the Risk of Fraudulent Practices